Prior Antidepressant Treatment Trials May Predict a Greater Risk of Depressive Relapse During Antidepressant Maintenance Therapy.

Abstract:

BACKGROUND:We examined the influence of prior antidepressant treatment trials on the likelihood of depressive relapse, and time to depressive relapse, during maintenance therapy of bipolar II disorder in treatment-responsive subjects who had recovered from a major depressive episode. METHODS:Data were derived from a prospective, randomized, double-blind trial of 148 adult subjects with bipolar II major depressive episode who were initially administered open-label fluoxetine monotherapy for 12 weeks. Remitters with a final Hamilton Rating Scale for Depression score of 8 or lower were then randomized to continuation therapy with either fluoxetine (n = 28), lithium (n = 26), or placebo (n = 27) for 50 additional weeks. RESULTS:An increase in the number of prior antidepressant treatment trials was significantly associated with a greater likelihood of depressive relapse for all treatment conditions taken together [odds ratio (OR) = 1.42, z = 2.49, P = 0.01] and for the 2 active treatment conditions together (OR = 1.51, z = 2.28, P = 0.02). An increase in the number of prior antidepressant trials was also associated with a trend-level shortening in the time to relapse for all treatment conditions taken together (hazard ratio = 1.15; confidence interval, 0.99-1.35; P = 0.07) and a significantly shorter time to relapse for subjects in the 2 active treatment conditions (hazard ratio = 1.30; confidence interval, 1.05-1.62; P = 0.02). CONCLUSIONS:These findings support prior evidence of a negative influence of the number of prior antidepressant treatment trials on the likelihood of response and suggest that the number of prior antidepressant trials may also be associated with a greater odds of depressive relapse, and a shorter time to relapse, during antidepressant maintenance therapy in recovered depressed subjects with bipolar II disorder.

journal_name

J Clin Psychopharmacol

authors

Amsterdam JD,Kim TT

doi

10.1097/JCP.0000000000001049

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

344-350

issue

4

eissn

0271-0749

issn

1533-712X

journal_volume

39

pub_type

临床试验,杂志文章
  • Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.

    abstract:PURPOSE/BACKGROUND:Extensive research has been conducted comparing the metabolic characteristics of older second-generation antipsychotics (SGAs); minimal data exist comparing the long-term metabolic effects of SGAs approved in the last 10 years. METHODS/PROCEDURES:A retrospective chart review of patients treated with...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001318

    authors: Greger J,Aladeen T,Lewandowski E,Wojcik R,Westphal E,Rainka M,Capote H

    更新日期:2021-01-01 00:00:00

  • Alprazolam in the treatment of obsessive symptoms.

    abstract::Four patients with obsessive-compulsive disorder (DSM-III and RDC) were treated in an open trial with alprazolam. Moderate to marked improvement was noted in the degree of obsessionality, anxiety with motor tension, and secondary affective changes. The mixed anxiolytic-antidepressant properties of alprazolam are theor...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Tollefson G

    更新日期:1985-02-01 00:00:00

  • Aripiprazole in schizophrenia with cocaine dependence: a pilot study.

    abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000169419.38899.5b

    authors: Beresford TP,Clapp L,Martin B,Wiberg JL,Alfers J,Beresford HF

    更新日期:2005-08-01 00:00:00

  • Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.

    abstract:BACKGROUND:Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested tha...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000956

    authors: Ngai YF,Devlin AM,Panagiotopoulos C

    更新日期:2018-12-01 00:00:00

  • Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

    abstract:INTRODUCTION:One of the major enzymes of the cytochrome P450 drug-metabolizing system, CYP2D6, shows a high degree of genetic polymorphism and variability in activity. Based on the degree of CYP2D6 activity, individuals can be broadly classified as poor metabolizers (PMs) or extensive metabolizers (EMs); the metabolism...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181acc4dd

    authors: Nichols AI,Lobello K,Guico-Pabia CJ,Paul J,Preskorn SH

    更新日期:2009-08-01 00:00:00

  • Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels.

    abstract::Many drugs, including alcohol and stimulants, demonstrably increase sociability and verbal interaction and are recreationally consumed in social settings. One drug, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), seems to produce its prosocial effects by increasing plasma oxytocin levels, and the oxytocin system ha...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000314

    authors: Bershad AK,Kirkpatrick MG,Seiden JA,de Wit H

    更新日期:2015-06-01 00:00:00

  • Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.

    abstract:PURPOSE/BACKGROUND:To add to limited evidence on the Abnormal Involuntary Movement Scale (AIMS) as a measure of tardive dyskinesia (TD) in clinical practice settings, the characteristics and correlates of AIMS scores were assessed. METHODS/PROCEDURES:Veterans with schizophrenia/schizoaffective, bipolar, or major depre...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001229

    authors: Caroff SN,Leong SH,Roberts CB,Berkowitz RM,Campbell EC

    更新日期:2020-07-01 00:00:00

  • Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

    abstract::This paper examines the relationship between plasma concentration of antidepressant and both clinical response and adverse effects in treatment-resistant depressed adolescents. Adolescents (n = 334) with major depression who had not responded to a selective serotonin reuptake inhibitor (SSRI) were randomized to 1 of 4...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e318204b117

    authors: Sakolsky DJ,Perel JM,Emslie GJ,Clarke GN,Wagner KD,Vitiello B,Keller MB,Birmaher B,Asarnow JR,Ryan ND,McCracken JT,Strober MJ,Iyengar S,Porta G,Brent DA

    更新日期:2011-02-01 00:00:00

  • Interrater reliability of the modified Monitoring of Side Effects Scale for assessment of adverse effects of psychiatric medication in clinical and research settings.

    abstract::The assessment of adverse effects of psychiatric medications is important in clinical and research settings because they are often associated with medication discontinuation, symptom exacerbation, and reduced quality of life. Currently available assessment tools are either limited with regard to the number and variety...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000311

    authors: Nugent KL,Spahr E,Toroney J,Mojtabai R,Nettles C,Turner LW,Fenton A,Spivak A,Cullen BA,Everett A,Eaton WW

    更新日期:2015-06-01 00:00:00

  • Pharmacokinetics of benzodiazepines and psychostimulants in children.

    abstract::The pharmacokinetics of benzodiazepines and psychostimulants are reviewed and an overview of the kinetic principles relevant to the utilization of these drugs in infancy and childhood is provided. Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Coffey B,Shader RI,Greenblatt DJ

    更新日期:1983-08-01 00:00:00

  • Mianserin pharmacokinetics and behavior in hyperkinetic children.

    abstract::The present study was conducted to derive pediatric mianserin pharmacokinetic parameters, which were compared to those from healthy young adults, and to obtain preliminary information regarding the utility of mianserin for the management of hyperkinesis in children. The sample consisted of six prepubescent children wi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Winsberg BG,Camp-Bruno JA,Vink J,Timmer CJ,Sverd J

    更新日期:1987-06-01 00:00:00

  • Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.

    abstract::In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was moni...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200004000-00014

    authors: Ulrich S,Neuhof S,Braun V,Danos P,Pester U,Hoy L

    更新日期:2000-04-01 00:00:00

  • Desipramine plasma levels and response in elderly melancholic patients.

    abstract::The relationship of response and plasma desipramine concentrations was examined in elderly depressed patients to determine whether they were more sensitive to the antidepressant effects of the drug and whether they would respond at lower plasma concentrations than younger patients. Twenty-five inpatients over the age ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nelson JC,Jatlow PI,Mazure C

    更新日期:1985-08-01 00:00:00

  • Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.

    abstract::Pregabalin is a novel compound in development for the treatment of anxiety disorders. The safety and efficacy of pregabalin for the treatment of social anxiety disorder was evaluated in a double-blind, multicenter clinical trial in which 135 patients were randomized to 10 weeks of double-blind treatment with either pr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.jcp.0000117423.05703.e7

    authors: Pande AC,Feltner DE,Jefferson JW,Davidson JR,Pollack M,Stein MB,Lydiard RB,Futterer R,Robinson P,Slomkowski M,DuBoff E,Phelps M,Janney CA,Werth JL

    更新日期:2004-04-01 00:00:00

  • Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers.

    abstract::The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it has also been thought to mediate impulsive behaviors in animal models. Most of the studies of drug effects on impulsive behaviors in humans have involved drugs with complex actions on different transmitter systems and differ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3181602fab

    authors: Hamidovic A,Kang UJ,de Wit H

    更新日期:2008-02-01 00:00:00

  • Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.

    abstract::Cognitive dysfunction in patients with schizophrenia is a strong correlate of poor outcome than any other symptom domain. To have greater knowledge about the effects of antipsychotics on cognitive function, subjects of this study were healthy volunteers who had no confounding variables typically found in patients with...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e318272d10c

    authors: Chung YC,Park TW,Yang JC,Huang GB,Zhao T,Oh KY,Kim MG

    更新日期:2012-12-01 00:00:00

  • Amoxapine versus amitriptyline for continuation therapy of depression.

    abstract::The efficacy of continuation therapy with tricyclic antidepressants has been established in a number of controlled trials. This study investigated the efficacy of continuation therapy with a relatively new antidepressant, amoxapine, using a double-blind controlled comparison with amitriptyline. Subjects met DSM-III cr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Mason BJ,Kocsis JH,Frances AJ,Mann JJ

    更新日期:1990-10-01 00:00:00

  • Unaltered Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia After 6 Months of Antipsychotics Treatment: A Naturalistic Study.

    abstract:BACKGROUND:Dopaminergic dysfunction, namely, dopamine transporter (DAT) availability variations in patients with drug-naive schizophrenia after long-term treatment, is still not well understood. The aims of the study were to explore (i) whether the DAT availability in patients with drug-naive schizophrenia differed aft...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000632

    authors: Chang WH,Chen KC,Lee IH,Chi MH,Chen PS,Yao WJ,Chiu NT,Yang YK

    更新日期:2017-02-01 00:00:00

  • Persistence of fluphenazine in plasma after decanoate withdrawal.

    abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gitlin MJ,Midha KK,Fogelson D,Nuechterlein K

    更新日期:1988-02-01 00:00:00

  • Clozapine Titration for People in Early Psychosis: A Chart Review and Treatment Guideline.

    abstract:PURPOSE/BACKGROUND:The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000860

    authors: Ballon JS,Ashfaq H,Noordsy DL

    更新日期:2018-06-01 00:00:00

  • Pharmacokinetics of valproate and carbamazepine.

    abstract::Over the past 10 years, knowledge gained about the pharmacokinetic profiles of valproate and carbamazepine has increased the clinical effectiveness of their use. Much of the information has been gained through their use as successful antiepileptic medications. As these agents begin to play an increasing role as mood-s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199202001-00010

    authors: Wilder BJ

    更新日期:1992-02-01 00:00:00

  • Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

    abstract::The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose and 2 flexible-dose m...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000416

    authors: McIntyre RS,Gorwood P,Thase ME,Liss C,Desai D,Chen J,Bauer M

    更新日期:2015-12-01 00:00:00

  • Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.

    abstract::In an open label study, two fixed doses of nifedipine (30 mg and 60 mg daily) were added to the usual antipsychotic drug treatments of 10 patients suffering from chronic schizophrenia. While no patient experienced significant improvements, statistically significant falls in Brief Psychiatric Rating Scales scores were ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Stedman TJ,Whiteford HA,Eyles D,Welham JL,Pond SM

    更新日期:1991-02-01 00:00:00

  • Double-blind, placebo-controlled study of single-dose metergoline in depressed patients with seasonal affective disorder.

    abstract::A role for serotonin in season affective disorder (SAD) has been explored with a variety of serotonergic pharmacologic agents. The authors initially hypothesized that metergoline, a nonspecific serotonin antagonist, would exacerbate depressive symptoms. In a small, open-label pilot study, the authors observed the oppo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200204000-00018

    authors: Turner EH,Schwartz PJ,Lowe CH,Nawab SS,Feldman-Naim S,Drake CL,Myers FS,Barnett RL,Rosenthal NE

    更新日期:2002-04-01 00:00:00

  • α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.

    abstract:PURPOSE:The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 n...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0000000000000859

    authors: Jones C

    更新日期:2018-06-01 00:00:00

  • Clozapine and global cognition in schizophrenia.

    abstract:OBJECTIVE:Clozapine (CLZ) has been shown to have a beneficial effect on cognition in schizophrenia in some studies and a detrimental effect in others. The relative effect and exposure to CLZ and its major metabolite-N-desmethylclozapine (NDMC)-could explain these discrepancies. METHODS:Using a validated measure of glo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181e69060

    authors: Rajji TK,Uchida H,Ismail Z,Ng W,Mamo DC,Remington G,Pollock BG,Mulsant BH

    更新日期:2010-08-01 00:00:00

  • Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.

    abstract::This study evaluated the impact of using long-acting injectable (LAI) antipsychotics for a longer treatment duration versus a short duration on health care resource utilization among Medicaid-insured schizophrenia patients. Schizophrenia patients 13 years or older initiating LAI antipsychotics were identified from the...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182a6082a

    authors: Bera R,Offord S,Zubek D,Lau G,Lin J,Karson C

    更新日期:2014-02-01 00:00:00

  • Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.

    abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nagy LM,Krystal JH,Charney DS,Merikangas KR,Woods SW

    更新日期:1993-02-01 00:00:00

  • Substance-induced dissociative disorders and psychiatric nosology.

    abstract::Transient amnesias, fugues, twilight states, automatisms, depersonalization, and furors or explosive disorders can occur in association with, or be caused by, various medications or substance-induced organic brain states. Agents capable of precipitating dissociative-like states include alcohol, barbiturates and simila...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Good MI

    更新日期:1989-04-01 00:00:00

  • Comparative abuse liability of intravenously administered remifentanil and fentanyl.

    abstract::Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 mi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200012000-00002

    authors: Baylon GJ,Kaplan HL,Somer G,Busto UE,Sellers EM

    更新日期:2000-12-01 00:00:00